Search - tctmd.com

Displaying 21 - 30 of 30

$Hierarchical composite endpoints for heart failure trials - answering the question: What fraction of the composite endpoint is due to cardiovascular mortality, hospitalization, or quality of life?$

Presentation THT 2023

Hierarchical composite endpoints for heart failure trials - answering the question: What fraction of the composite endpoint is due to cardiovascular mortality, hospitalization, or quality of life?

Presenter: Michael Sutherland

March 21, 2023

Presentation THT 2023

Cardiovascular Hospitalization Rates in ATTR-CA: What Factors Make a Difference

Presenter: Margaret Cuomo

March 21, 2023

News Conference News THT 2023

TEER or VAD/Transplant in the Advanced HF Patient With MR?

Shelley Wood

March 20, 2023

News Conference News THT 2023

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

Todd Neale

March 20, 2023

Presentation THT 2023

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Presenter: William Abraham

March 20, 2023

News Conference News THT 2022

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

Caitlin E. Cox

February 07, 2022

News Conference News THT 2022

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

L.A. McKeown

February 03, 2022

Presentation THT 2022

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

Presenter: Akshay Desai

February 02, 2022

Presentation THT 2022

SCAI Stage Across Hospitalization and the Association of Time to Max Escalation and In-hospital Mortality Among Cardiogenic Shock Patients

Presenter: Shashank Sinha

February 02, 2022

Presentation THT 2022

The Effect of Rhythm vs. Rate Control for Atrial Fibrillation on Mortality and Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction: Updated Meta-Analysis

Presenter: Mohammed Al-Sadawi

February 01, 2022

Advertisement

Hierarchical composite endpoints for heart failure trials - answering the question: What fraction of the composite endpoint is due to cardiovascular mortality, hospitalization, or quality of life?

Cardiovascular Hospitalization Rates in ATTR-CA: What Factors Make a Difference

TEER or VAD/Transplant in the Advanced HF Patient With MR?

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

SCAI Stage Across Hospitalization and the Association of Time to Max Escalation and In-hospital Mortality Among Cardiogenic Shock Patients

The Effect of Rhythm vs. Rate Control for Atrial Fibrillation on Mortality and Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction: Updated Meta-Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content